Hot Features
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expres... Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0791 | 13.8771929825 | 0.57 | 0.7 | 0.565 | 2616955 | 0.64161863 | CS |
| 4 | -0.8509 | -56.7266666667 | 1.5 | 1.59 | 0.5451 | 4607725 | 0.64033344 | CS |
| 12 | -1.8509 | -74.036 | 2.5 | 3.12 | 0.5451 | 2014917 | 1.11577646 | CS |
| 26 | -1.0509 | -61.8176470588 | 1.7 | 3.62 | 0.5451 | 1643417 | 1.64486068 | CS |
| 52 | -0.0244 | -3.62286562732 | 0.6735 | 3.62 | 0.5451 | 1045515 | 1.55016014 | CS |
| 156 | -0.8109 | -55.5410958904 | 1.46 | 3.62 | 0.49 | 511970 | 1.52451959 | CS |
| 260 | -3.7909 | -85.3806306306 | 4.44 | 10.87 | 0.47 | 759446 | 2.93561642 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.